Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.97 AUD | -1.97% | -2.11% | +13.33% |
Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
Feb. 25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
Sales 2024 * | 384M 251M | Sales 2025 * | 429M 280M | Capitalization | 577M 377M |
---|---|---|---|---|---|
Net income 2024 * | -83M -54.17M | Net income 2025 * | -2M -1.31M | EV / Sales 2024 * | 1.31 x |
Net cash position 2024 * | 72.1M 47.05M | Net cash position 2025 * | 60.91M 39.75M | EV / Sales 2025 * | 1.2 x |
P/E ratio 2024 * |
-6.95
x | P/E ratio 2025 * |
-207
x | Employees | 967 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
Latest transcript on Mayne Pharma Group Limited
1 day | -1.97% | ||
1 week | -2.11% | ||
Current month | -3.73% | ||
1 month | -3.86% | ||
3 months | +31.51% | ||
6 months | +84.88% | ||
Current year | +13.33% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Aaron Gray
DFI | Director of Finance/CFO | - | 22-08-28 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 18-05-29 |
Patrick Blake
BRD | Director/Board Member | 59 | 18-06-27 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 6.97 | -1.97% | 92 661 |
24-04-29 | 7.11 | +2.60% | 112,429 |
24-04-26 | 6.93 | -2.39% | 63,848 |
24-04-24 | 7.1 | -0.28% | 73,461 |
24-04-23 | 7.12 | +4.25% | 197,322 |
Delayed Quote Australian S.E., April 30, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.33% | 378M | |
+19.27% | 43.75B | |
+27.47% | 22.06B | |
+15.59% | 14.46B | |
+12.33% | 13.62B | |
+38.36% | 11.61B | |
-9.54% | 6.9B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+9.64% | 5.32B |
- Stock Market
- Equities
- MYX Stock